DUBLIN, July 13, 2017 /PRNewswire/ --
The "Antibiotics: the Quest for New Super Drugs: Technologies, Markets, Competitors and Opportunities: 2017-2022 Analysis and Forecasts" report has been added to Research and Markets' offering.
Antibiotics are drugs used to treat infections that are caused by bacteria. The introduction of antibiotics is recognized as one of the most transformative events in medicine. Prior to the introduction of the first antibiotics in the 1930s and 1940s, bacterial infections were often fatal, and invasive surgery was accompanied by a high risk of infectious complications.
Today, antibiotics are used routinely to treat and prevent infection. However, drug- and multi-drug-resistant bacterial strains pose a serious threat in the clinical setting as they directly contribute to an increase in morbidity and mortality, as compared to the underlying disease itself. Due to antibiotic resistance, new antibiotic super drugs are desperately needed to fight infections like MRSA, CRE, ESBLs and C. difficile. And that is beyond dealing with diseases like drug-resistant Gonorrhea, which affects an estimated 78 million people globally, or TB, which affects 10 million people worldwide, or even the 1 million+ people in the U.S. who get hospitalized with Pneumonia annually. Or bioweapons like Anthrax. Unfortunately, it is hard to discover new antibiotics.
Further compounding the problem, from approximately 20 traditional pharmaceutical companies investing in antibiotic research in the 1980s, there are now only five with significant active internal research programs. As a result, most novel antibiotic development is now being conducted by small biotech companies.
Over the last few years there has been a growing realization among the various stakeholders (Industry players, governments, authorities and medical charities) that something needs to be done to address the issues impacting antibiotic R&D, and avoid the looming socio-economic burden of antimicrobial resistance.
Current antibiotics work now, for the most part. But if an epidemic of one of the multi-drug-resistant strains rapidly spreading across the globe happens, it will be too late to start funding the discovery of new antibiotics. The need to invest is now, so there are options when the inevitable next black death appears. This report addresses these issues.
Key Topics Covered:
Methodology and Sources
2. Antibiotics Overview
Microbes in Context
Quest for Super Drugs
Gram-Positive vs. Gram-Negative Bacteria
Static vs. Cidal
Susceptibility, Potency and MIC
Efficacy and Safety
Mechanisms of Action
Resistance Is Nothing New
Costs of Antibiotic Resistance
Most Common Infections
Antibiotic Resistance Prevention
National Action Plan for Combating Antibiotic Resistant Bacteria
BARDA and NIAID Budgets
Presidential Advisory Council
United Kingdom Review on Antimicrobial Resistance
Margolis Center for Health Policy
21st Century Cures Act
MRSA on the Decline
CRE Poses an Urgent Threat
Failure Rate High
Carbapenems Use Increasing
ESBLs Pose a Serious Threat
New Delhi Metallo-Beta-Lactamase
Few New Antibiotics Being Produced
Cost of Trials
New Antibiotics Hard to Discover
Five Pharma Companies Left
Development Now Done by Startups
Numerous Studies on Situation
Alternative Is Unimaginable
3. Quest For Super Antibiotic Drugs
Discovery Platform Has Collapsed
New Antibiotic Discovery Process
Rationally Improve Existing Antibiotics
Rediscover Old Antibiotics
Repurpose Old Drugs
Discover Untested New Chemical Diversity
Community for Open Antimicrobial Drug Discovery
Long Time-Lower Success Rates
Focus for New Antibiotic Drugs Well Established
Dearth of New Antibiotic Drug Classes
R&D Development and Commercial Challenges
Modest Performance of New Antibiotics
Few Big Players Remain
New Key Initiatives
Growing Wave of Activity in Antibiotics
Activity Mostly Led by Biotechs
Antibiotics in Late Clinical Development
Obtaining Investments for New Antibiotics Is Difficult
Startups Believe They Can Find New Antibiotics
Antibiotics Approved in Recent Years
New Antibiotics That Have Received Marketing Authorization
Disappointing Sales Post-Launch
Beta-lactamases, Cephalosporinase and Carbapenemase Inhibitors
New Fluoroquinolones and DNA Gyrase Inhibitors
New Fatty Acid Biosynthesis Inhibitors
New Folate Biosynthesis Inhibitors
Old Antibiotics with New Dosing
Analogs of Existing Classes Still Difficult to Develop
New Oral Antibiotics for Outpatients Urgently Needed
New Oral Antibiotics for Children Urgently Needed
Government Incentives Needed
Options Market for Antibiotics
4. Antibiotics Market
Antibiotics Production Value
Production Value by Class
Production by Region
Consumption Volume Data
Antibiotic Market Volume
Consumption by Country
Class Differences by Country
Public Health Issues
Community Acquired Bacterial Pneumonia
Healthcare-Associated Infections Decreasing
Medicare Part D
Large Pharma Exits Antibiotics
Biotech Enters Antibiotics
Antibiotic Deal Making
Antibiotic Supply Chains
India and China Antibiotic Supply Chains
Antibiotic Pollution Issues
North China Pharmaceutical Group
CSPC Pharmaceutical Group/Inner Mongolia Changsheng Pharmaceuticals
Shandong Lukang Pharmaceuticals
Harbin Pharmaceutical Group
Mylan Laboratories Ltd.
Hetero Drugs Ltd.
5. Company Profiles
Appendix 1: Antibiotic Classes
Appendix 2: Regulation
Food, Drug, and Cosmetic Act
Foreign Clinical Trials
Special FDA Expedited Review and Approval Programs
Qualified Infectious Disease Product Exclusivity
- Achaogen Inc
- Actelion Ltd.
- AstaZeneca plc
- Atox Bio
- Basilea Pharmaceutica AG
- Cempra Inc
- CrystalGenomics, Inc.
- Cubist Pharmaceuticals, Inc.
- Destiny Pharma Ltd.
- Dong Wha Pharmaceuticals
- Durata Therapeutics, Inc.
- Eisai Co., Ltd.
- Furiex Pharmaceuticals, Inc.
- GlaxoSmithKline, Plc.
- Grupo Ferrer Internacional S.A.
- Insmed Incorporated
- KaloBios Pharmaceuticals, Inc.
- Melinta Therapeutics, Inc.
- Merck & Co., Inc
- MerLion Pharmaceuticals Pte Ltd
- MicuRx Pharmaceuticals, Inc.
- Nabriva Therapeutics AG
- Novartis AG
- Osel Inc
- Otonomy, Inc
- Otsuka Pharmaceutical Co. Ltd.
- Paratek Pharmaceuticals, Inc.
- Pfizer Inc
- Polyphor Ltd.
- Rebiotix, Inc
- Roche Holding AG
- Savara Pharmaceuticals
- Sequella, Incorporated
- Seres Therapeutics, Inc.
- Summit, plc
- TaiGen Biotechnology Co., Ltd.
- Tetraphase Pharmaceuticals, Inc
- The Medicines Company
- Theravance Biopharma Inc
For more information about this report visit https://www.researchandmarkets.com/research/5t3fwb/antibiotics_the
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets